Apogee Therapeutics (APGE) Assets Average (2023 - 2026)

Apogee Therapeutics (APGE) has 4 years of Assets Average data on file, last reported at $1.1 billion in Q1 2026.

• Assets Average for Q1 2026 came in at $1.1 billion, up 51.95% year-over-year; the trailing twelve-month figure through Mar 2026 was $1.1 billion (up 51.95% YoY), and the FY2025 annual result was $845.5 million, up 46.37% from the prior year.
• Assets Average improved to $1.1 billion in Q1 2026 per APGE's latest filing, from $781.6 million in the prior quarter.
• Over five years, Assets Average peaked at $1.1 billion in Q1 2026 and troughed at $278.5 million in Q3 2023.
• A 4-year average of $693.6 million and a median of $734.1 million in 2025 frame the typical range for Assets Average.
• The sharpest annual moves came in 2024 and 2025: Assets Average surged 183.07% in 2024, then decreased 18.58% in 2025.
• A 4-year view of Assets Average shows it stood at $413.9 million in 2023, then soared by 84.85% to $765.1 million in 2024, then increased by 2.16% to $781.6 million in 2025, then jumped by 42.7% to $1.1 billion in 2026.
• Business Quant data shows APGE's Assets Average at $1.1 billion in Q1 2026, $781.6 million in Q4 2025, and $642.0 million in Q3 2025.